301520 万邦医药
已收盘 07-24 15:00:00
资讯
新帖
简况
万邦医药:公司的临床研究业务中有与抗癌和抗艾滋相关的项目,目前均有序进行中
证券之星 · 07-24 19:02
万邦医药:公司的临床研究业务中有与抗癌和抗艾滋相关的项目,目前均有序进行中
万邦医药:公司在研发过程中暂未使用AI技术
证券之星 · 07-24 17:05
万邦医药:公司在研发过程中暂未使用AI技术
复星医药旗下万邦医药冻干制剂生产线通过欧盟GMP现场检查,质量管理获国际认可
证券之星 · 07-09
复星医药旗下万邦医药冻干制剂生产线通过欧盟GMP现场检查,质量管理获国际认可
万邦医药:公司半年度报告将于2024年8月23日披露
证券之星 · 06-28
万邦医药:公司半年度报告将于2024年8月23日披露
万邦医药:截止2024年6月20日公司股东人数为10,757户
证券之星 · 06-25
万邦医药:截止2024年6月20日公司股东人数为10,757户
万邦医药(301520)6月24日主力资金净卖出686.48万元
证券之星 · 06-25
万邦医药(301520)6月24日主力资金净卖出686.48万元
京新药业:公司与万邦医药没有关系
证券之星 · 06-20
京新药业:公司与万邦医药没有关系
万邦医药(301520)6月18日主力资金净卖出2031.05万元
证券之星 · 06-19
万邦医药(301520)6月18日主力资金净卖出2031.05万元
万邦医药(301520)6月14日主力资金净卖出639.57万元
证券之星 · 06-17
万邦医药(301520)6月14日主力资金净卖出639.57万元
万邦医药(301520.SZ)2023年度每10股派5元 股权登记日为6月20日
智通财经 · 06-14
万邦医药(301520.SZ)2023年度每10股派5元 股权登记日为6月20日
万邦医药:公司已开发出司美格鲁肽的样本分析方法,属于临床研究环节之一,目前暂无相关订单
证券之星 · 06-05
万邦医药:公司已开发出司美格鲁肽的样本分析方法,属于临床研究环节之一,目前暂无相关订单
万邦医药(301520)5月23日主力资金净买入175.21万元
证券之星 · 05-24
万邦医药(301520)5月23日主力资金净买入175.21万元
万邦医药:公司暂未开展针对KP.2变异株的药物研发工作
证券之星 · 05-20
万邦医药:公司暂未开展针对KP.2变异株的药物研发工作
万邦医药(301520)5月15日主力资金净卖出944.62万元
证券之星 · 05-16
万邦医药(301520)5月15日主力资金净卖出944.62万元
万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户
证券之星 · 05-07
万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户
万邦医药:公司暂无合成生物技术
证券之星 · 05-06
万邦医药:公司暂无合成生物技术
万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户
证券之星 · 04-23
万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户
万邦医药(301520.SZ)发布2023年度业绩,净利润1.08亿元,增长9.48%
智通财经网 · 04-19
万邦医药(301520.SZ)发布2023年度业绩,净利润1.08亿元,增长9.48%
万邦医药跌2.69% 去年9月份上市超募5.4亿元
中国经济网 · 03-15
万邦医药跌2.69% 去年9月份上市超募5.4亿元
加载更多
公司概况
公司名称:
安徽万邦医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2023-09-25
主营业务:
安徽万邦医药科技股份有限公司主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司的服务主要分为药学研究服务和临床研究服务两大类。近年来,公司获得了高新技术企业、中国医药外包公司20强、中国医药守法诚信企业、合肥高新区瞪羚企业、安徽省企业技术中心、安徽省专精特新中小企业等多个荣誉称号。
发行价格:
67.88
{"stockData":{"symbol":"301520","market":"SZ","secType":"STK","nameCN":"万邦医药","latestPrice":38.96,"timestamp":1721804622000,"preClose":39.5,"halted":0,"volume":638100,"delay":0,"floatShares":16666700,"shares":66666700,"eps":1.6919,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.54,"latestTime":"07-24 15:00:00","open":39.3,"high":39.98,"low":38.85,"amount":25035800,"amplitude":0.0286,"askPrice":38.97,"askSize":6,"bidPrice":38.96,"bidSize":1,"shortable":0,"etf":0,"ttmEps":1.6919,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721871000000},"adr":0,"adjPreClose":39.5,"symbolType":"stock","openAndCloseTimeList":[[1721784600000,1721791800000],[1721797200000,1721804400000]],"highLimit":43.45,"lowLimit":35.55,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":66666667,"pbRate":1.76,"roa":"--","roe":"2.01%","epsLYR":2,"committee":0.018349,"marketValue":2597000000,"floatMarketCap":649000000,"peRate":23.027365,"changeRate":-0.0137,"turnoverRate":0.0383,"status":1},"requestUrl":"/m/hq/s/301520","defaultTab":"news","newsList":[{"id":"2453470070","title":"万邦医药:公司的临床研究业务中有与抗癌和抗艾滋相关的项目,目前均有序进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2453470070","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453470070?lang=zh_cn&edition=full","pubTime":"2024-07-24 19:02","pubTimestamp":1721818967,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)07月24日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司有抗癌或抗艾滋的项目吗,目前正在进行的项目有哪些,进展如何万邦医药董秘:尊敬的投资者您好,公司的临床研究业务中有与抗癌和抗艾滋相关的项目,目前均有序进行中,谢谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072400041672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2453307595","title":"万邦医药:公司在研发过程中暂未使用AI技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2453307595","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453307595?lang=zh_cn&edition=full","pubTime":"2024-07-24 17:05","pubTimestamp":1721811920,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)07月24日在投资者关系平台上答复投资者关心的问题。投资者:Ai趋势,请问贵公司在研发过程中有使用AI技术吗,或者有相关规划吗万邦医药董秘:尊敬的投资者您好,公司在研发过程中暂未使用AI技术,谢谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072400039211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2450058405","title":"复星医药旗下万邦医药冻干制剂生产线通过欧盟GMP现场检查,质量管理获国际认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2450058405","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450058405?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:26","pubTimestamp":1720488374,"startTime":"0","endTime":"0","summary":"近日,复星医药旗下万邦医药的冻干制剂生产线顺利通过欧盟GMP现场检查,并收到了荷兰卫生监督机构Health and Youth Care Inspectorate签发的GMP现场检查最终报告、检查关闭信及GMP检查证书,标志着其质量管理体系和生产能力再次得到国际权威认证机构的认可,进一步提升了公司的全球竞争力。该生产线于2019年首次通过欧盟GMP现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024070900014248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0175","BK1515","02196","BK0012","BK1593","BK0196","BK0216","600196","BK0096","BK0188","BK0060","BK0239","BK1191","BK0187","301520","BK0028"],"gpt_icon":0},{"id":"2446575304","title":"万邦医药:公司半年度报告将于2024年8月23日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2446575304","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446575304?lang=zh_cn&edition=full","pubTime":"2024-06-28 17:04","pubTimestamp":1719565469,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)06月28日在投资者关系平台上答复投资者关心的问题。投资者:董秘你好!贵司的二季度财报什么时候发布万邦医药董秘:尊敬的投资者您好,公司半年度报告将于2024年8月23日披露,感谢关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800037158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2446819409","title":"万邦医药:截止2024年6月20日公司股东人数为10,757户","url":"https://stock-news.laohu8.com/highlight/detail?id=2446819409","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446819409?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:02","pubTimestamp":1719313370,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)06月25日在投资者关系平台上答复投资者关心的问题。投资者:请问截至2024年6月 20日公司的股东总数是多少?谢谢万邦医药董秘:尊敬的投资者您好,截止2024年6月20日公司股东人数为10,757户,感谢关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500035927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2446837446","title":"万邦医药(301520)6月24日主力资金净卖出686.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446837446","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446837446?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:22","pubTimestamp":1719278539,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月24日收盘,万邦医药报收于40.68元,下跌6.31%,换手率11.51%,成交量1.92万手,成交额7961.2万元。近5日资金流向一览见下表:万邦医药融资融券信息显示,融资方面,当日融资买入455.59万元,融资偿还601.51万元,融资净偿还145.93万元。万邦医药主营业务:为药品生产企业或药品上市许可持有人提供药品研发和临床试验的全流程外包服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500010128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2444755260","title":"京新药业:公司与万邦医药没有关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2444755260","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444755260?lang=zh_cn&edition=full","pubTime":"2024-06-20 17:03","pubTimestamp":1718874187,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业06月20日在投资者关系平台上答复投资者关心的问题。公司与万邦医药没有关系。公司实际控制人及持股5%以上的股东没有参与转融通业务,公司会严格遵守信披规定,对大股东的须披露交易和市场行为进行披露。另外,公司前十大股东信息请关注公司定期报告披露内容,根据公司2024年第一季度报告,泰康人寿不是当期前十大股东之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000033325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","002020","301520","BK0239"],"gpt_icon":0},{"id":"2444990314","title":"万邦医药(301520)6月18日主力资金净卖出2031.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444990314","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444990314?lang=zh_cn&edition=full","pubTime":"2024-06-19 09:16","pubTimestamp":1718759779,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月18日收盘,万邦医药报收于43.88元,下跌2.49%,换手率15.36%,成交量2.56万手,成交额1.13亿元。近5日资金流向一览见下表:万邦医药融资融券信息显示,融资方面,当日融资买入1231.44万元,融资偿还971.78万元,融资净买入259.67万元。万邦医药主营业务:为药品生产企业或药品上市许可持有人提供药品研发和临床试验的全流程外包服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900014858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2444008349","title":"万邦医药(301520)6月14日主力资金净卖出639.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444008349","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444008349?lang=zh_cn&edition=full","pubTime":"2024-06-17 09:18","pubTimestamp":1718587128,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月14日收盘,万邦医药报收于45.23元,下跌3.25%,换手率15.44%,成交量2.57万手,成交额1.16亿元。近5日资金流向一览见下表:万邦医药融资融券信息显示,融资方面,当日融资买入941.34万元,融资偿还822.59万元,融资净买入118.75万元,连续3日净买入累计1229.11万元。万邦医药主营业务:为药品生产企业或药品上市许可持有人提供药品研发和临床试验的全流程外包服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700001845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2443962292","title":"万邦医药(301520.SZ)2023年度每10股派5元 股权登记日为6月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2443962292","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443962292?lang=zh_cn&edition=full","pubTime":"2024-06-14 20:47","pubTimestamp":1718369235,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万邦医药(301520.SZ)发布公告,公司将实施2023年年度权益分派,每10股派发现金红利5元(含税),股权登记日为6月20日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301520","BK0216"],"gpt_icon":0},{"id":"2441324726","title":"万邦医药:公司已开发出司美格鲁肽的样本分析方法,属于临床研究环节之一,目前暂无相关订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2441324726","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441324726?lang=zh_cn&edition=full","pubTime":"2024-06-05 17:04","pubTimestamp":1717578260,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药06月05日在投资者关系平台上答复投资者关心的问题。公司已开发出司美格鲁肽的样本分析方法,属于临床研究环节之一,目前暂无相关订单。公司的经营情况稳定,详情请见公司披露的定期报告,感谢您的关注。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500034539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2437747795","title":"万邦医药(301520)5月23日主力资金净买入175.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437747795","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437747795?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:15","pubTimestamp":1716513321,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月23日收盘,万邦医药报收于45.76元,上涨1.19%,换手率7.72%,成交量1.29万手,成交额5860.07万元。近5日资金流向一览见下表:万邦医药融资融券信息显示,融资方面,当日融资买入313.15万元,融资偿还346.95万元,融资净偿还33.8万元。万邦医药主营业务:为药品生产企业或药品上市许可持有人提供药品研发和临床试验的全流程外包服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400015317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2436512794","title":"万邦医药:公司暂未开展针对KP.2变异株的药物研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2436512794","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436512794?lang=zh_cn&edition=full","pubTime":"2024-05-20 17:03","pubTimestamp":1716195834,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药05月20日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的万邦医药董秘:您好,针对新冠病毒变异株KP.2的流行情况,考虑到贵公司在生物医药领域的专业能力和研发实力,我想了解万邦医药是否已经开展了针对KP.2变异株的药物研发工作?万邦医药董秘:尊敬的投资者您好,公司暂未开展针对KP.2变异株的药物研发工作,感谢您的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052000017686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2435187906","title":"万邦医药(301520)5月15日主力资金净卖出944.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435187906","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435187906?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:22","pubTimestamp":1715822537,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月15日收盘,万邦医药报收于44.78元,下跌2.65%,换手率8.12%,成交量1.35万手,成交额6077.51万元。近5日资金流向一览见下表:万邦医药融资融券信息显示,融资方面,当日融资买入585.23万元,融资偿还302.93万元,融资净买入282.3万元,连续3日净买入累计954.7万元。万邦医药主营业务:为药品生产企业或药品上市许可持有人提供药品研发和临床试验的全流程外包服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600010227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2433327430","title":"万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户","url":"https://stock-news.laohu8.com/highlight/detail?id=2433327430","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433327430?lang=zh_cn&edition=full","pubTime":"2024-05-07 19:03","pubTimestamp":1715079811,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)05月07日在投资者关系平台上答复投资者关心的问题。投资者:请问截止2024年5月6日,公司持股股东人数是多少?万邦医药董秘:尊敬的投资者您好,根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户,感谢关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700032025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2433440843","title":"万邦医药:公司暂无合成生物技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2433440843","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433440843?lang=zh_cn&edition=full","pubTime":"2024-05-06 18:04","pubTimestamp":1714989896,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)05月06日在投资者关系平台上答复投资者关心的问题。投资者:您好,请问公司有合成生物技术吗?万邦医药董秘:尊敬的投资者您好,公司暂无合成生物技术,感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600020566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2429164802","title":"万邦医药:根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164802","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429164802?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:04","pubTimestamp":1713866682,"startTime":"0","endTime":"0","summary":"证券之星消息,万邦医药(301520)04月23日在投资者关系平台上答复投资者关心的问题。投资者:请问截止2024年4月22日,公司股东人数多少?万邦医药董秘:尊敬的投资者您好,根据已披露的2024年第一季度报告,截止2024年3月31日公司股东人数为8566户,感谢关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301520"],"gpt_icon":0},{"id":"2428658546","title":"万邦医药(301520.SZ)发布2023年度业绩,净利润1.08亿元,增长9.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428658546","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428658546?lang=zh_cn&edition=full","pubTime":"2024-04-19 19:28","pubTimestamp":1713526080,"startTime":"0","endTime":"0","summary":"万邦医药发布2023年年度报告,该公司营业收入为3.42亿元,同比增长31.07%。归属于上市公司股东的净利润为1.08亿元,同比增长9.48%。基本每股收益为2元。此外,拟向全体股东每10股派发现金红利5元(含税)。公告显示,公司是一家同时提供药学研究和临床研究服务的综合型CRO企业,通过合同形式为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司成立于2006年,是国内较早提供药物研发服务的CRO企业之一。股市回暖,抄底炒股先开户!","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-19/doc-inaskmiq9535419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301520"],"gpt_icon":0},{"id":"2419941815","title":"万邦医药跌2.69% 去年9月份上市超募5.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419941815","media":"中国经济网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419941815?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:21","pubTimestamp":1710490860,"startTime":"0","endTime":"0","summary":" 万邦医药于2023年9月25日在深交所创业板上市,公开发行股票1,666.6667万股,占发行后公司股份总数的比例为25.00%,全部为新股发行,原股东不公开发售股份,发行价格为67.88元/股,保荐机构为民生证券股份有限公司,保荐代表人为王璐、傅德福。 万邦医药首次公开发行募集资金总额为113,133.34万元,扣除发行费用后募集资金净额为102,430.09万元。 万邦医药发行费用总额为10,703.25万元,其中民生证券股份有限公司获得保荐及承销费用7,919.33万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-03-15/doc-inankyam8459818.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-03-15/doc-inankyam8459818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301520","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-09-25","address":"安徽省合肥市蜀山区高新区明珠大道与火龙地路交口西南角安徽万邦医药1号楼","stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0423},{"period":"3month","weight":-0.1037},{"period":"6month","weight":-0.2729},{"period":"1year","weight":-0.426},{"period":"ytd","weight":-0.2875}],"companyName":"安徽万邦医药科技股份有限公司","boardCode":"AI0073","perCapita":"1549股","boardName":"研究和试验发展","registeredCapital":"6666万元","compareEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":-0.0206},{"period":"3month","weight":-0.0494},{"period":"6month","weight":-0.0028},{"period":"1year","weight":-0.102},{"period":"ytd","weight":-0.0245}],"survey":" 安徽万邦医药科技股份有限公司主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司的服务主要分为药学研究服务和临床研究服务两大类。近年来,公司获得了高新技术企业、中国医药外包公司20强、中国医药守法诚信企业、合肥高新区瞪羚企业、安徽省企业技术中心、安徽省专精特新中小企业等多个荣誉称号。","serverTime":1721852131836,"listedPrice":67.88,"stockholders":"10757人(较上一季度增加25.58%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万邦医药(301520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万邦医药(301520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万邦医药,301520,万邦医药股票,万邦医药股票老虎,万邦医药股票老虎国际,万邦医药行情,万邦医药股票行情,万邦医药股价,万邦医药股市,万邦医药股票价格,万邦医药股票交易,万邦医药股票购买,万邦医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万邦医药(301520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万邦医药(301520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}